A Study of a New Investigational Medicinal Product to Treat Patients With Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
W0101 combines a cytotoxic compound to a monoclonal antibody targeting a receptor commonly
overexpressed in many cancers.
The development of antibody-drug conjugates takes advantage of the specificity of the mAb
while augmenting its ability to produce a cytotoxic effect. The expected benefits of
antibody-drug conjugation are enhancement of cytotoxicity in target cells and limiting
toxicities of cytotoxic drugs in normal tissues.